These results indicated that TCR signaling pathway exerts diverse effects in response to DOS, XELOX, as well as XELOX combined with anti-HER2 targeted therapy, which assist to determine the appropriate chemotherapy and targeted therapeutic strategy for GC patients. Here, ERBB2 is linked to gastric cancer.